Rashmi Murthy

12PUBLICATIONS
111CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 22, 2026
Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.

|Mar 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results.

Rashmi K Murthy, Barbara J O'Brien, Donald A Berry

|Jan 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.

Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava

|Oct 02, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.

Clinton Yam, Miral Patel, Holly A Hill

|Dec 15, 2023
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.

Fatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier

|Oct 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.

Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita

Pageof 2

Frequent Collaborators

6 joint publications

Debu Tripathy

3 joint publications

Gaiane M Rauch

3 joint publications

Akshara Singareeka-Raghavendra

3 joint publications

Gabriel N Hortobagyi